← Back to Search

Lidocaine for Sexual Dysfunction

Phase 4
Waitlist Available
Led By David Bender, MD
Research Sponsored by David Bender
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Female
Age 18-99
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 9 months
Awards & highlights

Study Summary

This study is evaluating whether a cream applied to the vagina may help reduce pain during sexual intercourse for women who have had surgery for gynecologic cancer.

Eligible Conditions
  • Gynecologic Cancers
  • Sexual Dysfunction

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~9 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 9 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Changes in Pain
Changes in Sexual Function
Secondary outcome measures
Adverse Childhood Events
Anxiety
Depressive Symptoms
+5 more

Trial Design

2Treatment groups
Active Control
Placebo Group
Group I: LidocaineActive Control1 Intervention
Patients being treated for gynecologic cancer assigned aqueous lidocaine solution as intervention to use during sexual encounters.
Group II: PlaceboPlacebo Group1 Intervention
Patients being treated for gynecologic cancer assigned placebo solution as intervention to use during sexual encounters.

Find a Location

Who is running the clinical trial?

David BenderLead Sponsor
David Bender, MDPrincipal Investigator - University of Iowa
University of Iowa Chemical Dependency Center, University of Iowa Hospitals & Clinics
Finch U Of Hs/Chicago Medical Sch (Medical School)
University Hlth Ctr Of Pittsburgh (Residency)

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
~1 spots leftby Mar 2025